Dr. Reddy's Laboratories Ltd.
8-2-337, Road No. 3, Banjara Hills,
Hyderabad - 500 034, Telangana,
India.
CIN : L85195TG1984PLC004507

Tel :+91 40 4900 2900
Fax :+91 40 4900 2999
Email :mail@drreddys.com
www.drreddys.com

April 27, 2020

Corporate Relationship Department
BSE Limited
Dalal Street, Fort
Mumbai – 400 001
Fax Nos.: 022-22723121 / 22723719 /
22722037 / 22722039

**Scrip Code: 500124**

National Stock Exchange of India Ltd.
"Exchange Plaza"
Bandra-Kurla Complex, Bandra (East),
Mumbai – 400 051
Fax Nos.: 022-26598120/ 26598237/
26598238

**Scrip Code: DRREDDY-EQ**

Dear Sirs,

**Sub: Press Release**

Please find enclosed a Press Release on **"Dr. Reddy's Laboratories announces the launch of Fenofibrate Tablets USP, in the U.S. Market."**

This is for your information.

With regards,

SANDEEP PODDAR
Digitally signed by SANDEEP PODDAR
Date: 2020.04.27 11:29:42 +05'30'

Sandeep Poddar
Company Secretary

Encl: As above

CC:- New York Stock Exchange Inc.(Stock Code: RDY)

# Press Release

Dr.Reddy's

**DR. REDDY'S LABORATORIES LTD.**
8-2-337, Road No. 3, Banjara Hills,
Hyderabad - 500034. Telangana, India.

| CONTACT | |
|---|---|
| **INVESTOR RELATIONS** | **MEDIA RELATIONS** |
| AMIT AGARWAL<br>amita@drreddys.com<br>(PH: +91-40-49002135) | APARNA TEKURI<br>aparnatekuri@drreddys.com<br>(PH: +91-40- 49002121) |

## Dr. Reddy's Laboratories announces the launch of Fenofibrate Tablets USP, in the U.S. Market

**Hyderabad, India, April 27, 2020** **For Immediate Release**

Hyderabad, India and Princeton, NJ, USA. April 27, 2020 — Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as "Dr. Reddy's") today announced the launch of Fenofibrate Tablets USP, a therapeutic equivalent generic version of Tricor® (fenofibrate) Tablets, approved by the U.S. Food and Drug Administration (USFDA).

The Tricor® brand and generic had U.S. sales of approximately $90 million MAT for the most recent twelve months ending in January 2020 according to IQVIA Health*.

Dr. Reddy's Fenofibrate Tablets USP, are available in 54 mg dose in bottle count size of 90 and 160 mg dose in bottle count sizes of 90 and 500.

Tricor® is a trademark of AbbVie Inc.

SANDEEP PODDAR Digitally signed by SANDEEP PODDAR Date: 2020.04.27 11:30:16 +05'30'

*IQVIA Retail and Non-Retail MAT January 2020.

RDY-0320-279

**About Dr. Reddy's**: Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy's operates in markets across the globe. Our major markets include – USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com

**Disclaimer**: This press release may include statements of future expectations and other forward-looking statements that are based on the management's current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates , interest rates , persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization , including related integration issues.

The company assumes no obligation to update any information contained herein.